Posts Tagged ‘Gesellschaft mit beschränkter Haftung’

In Cambridge, MA — Boehringer Ingelheim Venture Fund Gmbh Establishes U.S. Operations

Reporter: Aviva Lev-Ari, PhD, RN

Ridgefield, Conn., (December 2, 2013):  Boehringer Ingelheim today announced that the Boehringer Ingelheim Venture Fund GmbH (BIVF) has opened a U.S. office in the premier biotech hub of Kendall Square in Cambridge, Mass. BIVF is a private equity fund created to invest in biotech and start-up companies which provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science.

The U.S. office will be led by Martin Heidecker, who will operate from Cambridge as well as Boehringer Ingelheim’s Fremont, California site, located in the heart of the San Francisco Bay Area biotech cluster. BIVF will invest up to approximately $13 million dollars per company, with a total fund volume of $130 million dollars.

“What makes BIVF unique is that we can help establish companies from the beginning, which can foster a conducive environment for innovation and enable greater success. Our U.S. presence means more opportunities for break-through biomedical initiatives, and we are looking forward to uncovering top talent in this exciting and entrepreneurial U.S. market,” said Heidecker.

BIVF will provide added-value expertise beyond capital investment, leveraging Boehringer Ingelheim’s extensive drug discovery, scientific and managerial proficiency. The team will specifically seek out investment opportunities unrelated to Boehringer Ingelheim’s key therapeutic areas.  BIVF’s ultimate goal is to enhance those companies invested in, delivering success for them and generating revenues to finance further new investment to benefit patients.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.us.boehringer-ingelheim.com.



Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN


In this Journal Stent technology was researched thoroughly, the reader is advised to enrich his/hers knowledge on Re-vascularization technology by reviewing the following articles and the bibliography in each of them:

Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents

Aviva Lev-Ari, PhD, RN 8/13/2012

Drug Eluting Stents: On MIT’s Edelman Lab’s Contributions to Vascular Biology and its Pioneering Research on DES

Larry H Bernstein, MD, FACP, Author and  Aviva Lev-Ari, PhD, RN, Curator 4/25/2013

Vascular Repair: Stents and Biologically Active Implants

Larry H Bernstein, MD, FACP, Author and  Aviva Lev-Ari, PhD, RN, Curator 5/4/2013

Biomaterials Technology: Models of Tissue Engineering for Reperfusion and Implantable Devices for Revascularization 5/5/2013

Revascularization: PCI, Prior History of PCI vs CABG

Aviva Lev-Ari, PhD, RN 4/25/2013

To Stent or Not? A Critical Decision

Aviva Lev-Ari, PhD, RN 10/23/2012

New Drug-Eluting Stent Works Well in STEMI

Aviva Lev-Ari, PhD, RN 8/22/2012

OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings

May 21, 2013

OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings

WIESBADEN, Germany, May 21, 2013 /PRNewswire/ — Medical device manufacturer OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively “OrbusNeich”) today announced that it has enforced the seizure of over 190 stent systems from Boston Scientific Corporation (NYSE: BSX) in connection with its patent infringement proceedings in the Dusseldorf Regional Court. The products were found on May 15, 2013, at the premises of Boston Scientific Medizintechnik GmbH in Ratingen (Germany), the German subsidiary of Boston Scientific Corporation (collectively “Boston Scientific”).

In violation of the Court’s April 30, 2013 Preliminary Injunction, Boston Scientific initially denied access to search its premises – the court’s decision grants OrbusNeich the right to seize stents in the possession of Boston Scientific that have been commercially distributed but not yet used. Boston Scientific claimed that none of the concerned stent systems were in its possession at the location in Ratingen. Only after the Police were called did Boston Scientific allow the bailiff to search the building and seize the products.

The April 30, 2013, ruling, which Boston Scientific has appealed, allows OrbusNeich to prevent Boston Scientific from marketing and selling the affected stent lines in Germany, which include the Small Vessel, Small Workhorse and Workhorse Stents of Boston Scientific’s PROMUS Element™, PROMUS Element Plus™, OMEGA™, TAXUS Element™, SYNERGY™ and Promus PREMIER™ product lines. In this decision, the Regional Court found that the geometric pattern of these stents infringe OrbusNeich’s patent EP 1 341 482.

On May 13, 2013, OrbusNeich obtained a second Preliminary Injunction against Boston Scientific following Boston Scientific’s attempt to circumvent the first Injunction by transferring the German distribution of the affected products to Boston Scientific (UK) Ltd. and Boston Scientific Ltd. Boston Scientific may appeal this decision.

In addition to the Preliminary Injunctions, OrbusNeich’s principal patent infringement proceedings are also before the Dusseldorf Regional Court. In these proceedings, OrbusNeich is seeking damages, a permanent injunction and other relief for alleged infringement of the German parts of the EP 1 341 412 and ‘482 patents by the affected stent lines. A hearing in this main proceeding is scheduled for May 2014.

Similar infringement proceedings have also been filed in The Netherlands and Ireland.

The proceedings follow a favorable ruling for OrbusNeich by the European Patent Office (EPO) on February 11, 2013, in connection with the ‘482 patent. The EPO decision, which has been appealed, upheld the claim of the ‘482 patent, as amended, against an opposition by Boston Scientific and Terumo, claiming the patent was invalid.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world’s first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Media Contact:
Jed Repko – Bryan Darrow – Taylor Ingraham
Joele Frank , Wilkinson Brimmer Katcher

SOURCE: OrbusNeich Medical Inc.

Read more: OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings – FierceMedicalDevices http://www.fiercemedicaldevices.com/press-releases/orbusneich-seizes-boston-scientific-stents-germany-part-patent-infringement#ixzz2TwxCAgth



Read Full Post »